Prevalence and duration of detectable SARS-CoV-2 nucleocapsid antibody in staff and residents of long-term care facilities over the first year of the pandemic (VIVALDI study): prospective cohort study
暂无分享,去创建一个
A. Copas | A. Hayward | M. Shrotri | L. Shallcross | T. Palmer | C. Fuller | P. Moss | M. Krutikov | B. Azmi | N. Kaur | P. Sylla | T. Lancaster | G. Tut | R. Giddings | A. Irwin-Singer
[1] A. Copas,et al. Profile of humoral and cellular immune responses to single doses of BNT162b2 or ChAdOx1 nCoV-19 vaccines in residents and staff within residential care homes (VIVALDI): an observational study , 2021, The Lancet Healthy Longevity.
[2] A. Copas,et al. Incidence of SARS-CoV-2 infection according to baseline antibody status in staff and residents of 100 long-term care facilities (VIVALDI): a prospective cohort study , 2021, The Lancet Healthy Longevity.
[3] S. Letovsky,et al. A population-based analysis of the longevity of SARS-CoV-2 antibody seropositivity in the United States , 2021, EClinicalMedicine.
[4] B. Ramos,et al. The Demography and Characteristic of SARS-CoV-2 Sero-positive Residents and Staff of Nursing Homes for Older Adults in the Community of Madrid: the SeroSOS Study , 2021, Age and ageing.
[5] C. Donnelly,et al. Prevalence of antibody positivity to SARS-CoV-2 following the first peak of infection in England: Serial cross-sectional studies of 365,000 adults , 2021, The Lancet Regional Health - Europe.
[6] V. Saliba,et al. Children develop strong and sustained cross-reactive immune responses against spike protein following SARS-CoV-2 infection , 2021, medRxiv.
[7] M. Picot,et al. Spike Antibody Levels of Nursing Home Residents With or Without Prior COVID-19 3 Weeks After a Single BNT162b2 Vaccine Dose. , 2021, JAMA.
[8] J. V. Van Eyk,et al. Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2 , 2021, Nature Network Boston.
[9] V. Simon,et al. Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine , 2021, The New England journal of medicine.
[10] M. Van Ranst,et al. Longitudinal follow-up of IgG anti-nucleocapsid antibodies in SARS-CoV-2 infected patients up to eight months after infection , 2021, Journal of Clinical Virology.
[11] A. Charlett,et al. Antibodies to SARS-CoV-2 protect against re-infection during outbreaks in care homes, September and October 2020 , 2021, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[12] R. Myers,et al. Infection and transmission of SARS-CoV-2 in London care homes reporting no cases or outbreaks of COVID-19: Prospective observational cohort study, England 2020 , 2021, The Lancet Regional Health - Europe.
[13] M. Malim,et al. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans , 2020, Nature Microbiology.
[14] J. Farrar,et al. Study Protocol: Understanding SARS-Cov-2 infection, immunity and its duration in care home residents and staff in England (VIVALDI). , 2020, Wellcome open research.
[15] B. Guthrie,et al. Evolution and effects of COVID-19 outbreaks in care homes: a population analysis in 189 care homes in one geographical region of the UK , 2020, The Lancet Healthy Longevity.
[16] G. Rodger,et al. Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison , 2020, The Lancet Infectious Diseases.
[17] C. Houlihan,et al. The complexities of SARS-CoV-2 serology , 2020, The Lancet Infectious Diseases.
[18] D. Cummings,et al. A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity , 2020, Nature Communications.
[19] A. Casadevall,et al. Comparative performance of five commercially available serologic assays to detect antibodies to SARS-CoV-2 and identify individuals with high neutralizing titers , 2020, medRxiv.
[20] A. Comas-Herrera,et al. COVID-19 mortality and long-term care: a UK comparison , 2020 .
[21] P. Rochon,et al. For-profit long-term care homes and the risk of COVID-19 outbreaks and resident deaths , 2020, Canadian Medical Association Journal.
[22] Otto O. Yang,et al. Rapid Decay of Anti–SARS-CoV-2 Antibodies in Persons with Mild Covid-19 , 2020, The New England journal of medicine.
[23] M. Wener,et al. Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence in Boise, Idaho , 2020, Journal of Clinical Microbiology.
[24] X. Tang,et al. Antibody responses to SARS-CoV-2 in patients with COVID-19 , 2020, Nature Medicine.
[25] J. Forder,et al. Length of stay in care homes , 2011 .
[26] A. Bebbington,et al. The length of stay in care , 1989 .